Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=843 Personalized Health Assessment Related to Medications (Project PHARM)
Feedback, Psychological · Clinical Trial · Substance Abuse
Primary: Change in Past 6 Month Non-Medical Use of Prescription Stimulant Medication Frequency — -2.04; -1.72; -1.03; -.38 Usage days — p=0.03
N/A N=160 Reducing Adverse Self-Medication Behaviors in Older Adults With Hypertension
Cardiovascular Diseases · Heart Diseases · Hypertension
Primary: Behaviors Risk Score — 17.9; 16.6; 16.4; 12.6 units on a scale — p=0.035
Phase 2 N=17 Medication Development for Opioid and Alcohol Abuse
Opioid-use Disorder · Alcohol Use Disorder
Primary: Peak Positive Subjective Responses to Placebo. — 3.3; 2.3 units on a scale
N/A N=235 Preventing Prescription Stimulant Diversion and Medication Misuse Via a Web-Based Simulation Intervention
Prescription Drug Abuse (Not Dependent) · Intentional Misuse
Primary: Frequency of Prescription Stimulant Diversion — .25; .41; .18; .30 Mean number of times diverted — p=.499
Phase 2 N=27 Prescription Opioid Effects in Abusers Versus Non-Abusers
Opioid-Related Disorders · Substance-Related Disorders
Primary: Breakpoint — 25; 400; 1400; 850 Mouse Clicks
Phase 1 N=80 Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
Nondependent Opioid Abuse, Episodic
Primary: Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours — 88.3; 100.3; 124.7 hrs*mm — p=<0.0001
N/A N=80 Mobile Application for Prescription Drug-Abuse Education (MAPDE)
Prescription Drug Abuse (Not Dependent)
Primary: Current Opioid Misuse Measure (COMM) — .72; .71; .62; .63 score on a scale — p=.72
N/A N=5,421 Medication Adherence Clinical Decision Support
Hyperlipidemia · Hypertension · Diabetes
Primary: Blood Pressure Medication Adherence — 396; 470 Participants — p=0.0103
Phase 2 N=19 Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients
Benzodiazepine Dependence · Opioid Dependence
Primary: Mean Reduction Change in Benzodiazepine Use Per Day Based on Time Line Follow Back — 4.0; 2.3 milligrams/day
Phase 1 N=25 Effects of Commonly Used Medications on Mood and Choice
Healthy
Primary: Participant Subjective Ratings of Drug Liking (Peak Change) — 1.00; -0.11; 0.88; 0.33 score on a scale
Phase 4 N=63 Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users
Abuse Potential
Primary: Drug Liking Visual Analog Scale (VAS) — 56.4; 84.9; 59.6; 64.6 score on a scale
Phase 2 N=49 Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
Opioid Abuse
Primary: Drug Liking at .5 Hours — 66.0; 74.7; 47.7; 40.9 score on a scale
Phase 2 N=30 Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
Opioid Abuse
Primary: Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min) — 11.7; 14.7 score on a scale
Phase 1 N=31 Staccato Alprazolam Abuse Liability
Abuse Liability of Staccato Alprazolam
Primary: Response to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again" — 0; 1.714; 2.143; 2.286 units on a scale
N/A N=19 The Adverse Drug Reaction (ADRe) Profile for Polypharmacy
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Phase 1 N=9 Buspirone as a Candidate Medication for Methamphetamine Abuse
Methamphetamine Dependence · Methamphetamine Abuse
Primary: Number of Methamphetamine Doses Self-Administered — 1.25; 0; 6.13; 4 Number of Methamphetamine Doses
Phase 4 N=51 An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users
Abuse Potential
Primary: Drug Liking "at This Moment" Visual Analog Scale (VAS) — 54.1; 83.8; 58.9; 58.4 score on a scale
N/A N=204 Safety & Prevention Outcomes Study
Drug Overdose · Opioid-Related Disorders
Primary: Overdose Risk Behavior — -1.54; -0.51 Scores on a scale
Phase 4 N=52 Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience
Abuse Potential
Primary: Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax). — 51.98; 79.37; 61.95; 61.39 Score on a scale — p=<0.0001
N/A N=60 Smart Capsule for Automatic Adherence Monitoring
Medication Adherence
Primary: Medication Adherence — 88.1; 96.6; 94.4 percentage of doses taken (pill count)
Phase 2 N=16 A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.
Opioid Use Disorder
Primary: Positive Subjective Drug Effects (i.e., Drug "Liking"). — 52.1; 57.5; 71.8; 71.5 units on a scale — p=.0001
N/A N=40 Assessing the Effectiveness and Safety of the ID-Cap System for Medication Monitoring and Adherence
Medication Adherence
Primary: Medication Adherence — 94.8; 82.8 percentage of doses taken
N/A N=50 Effects of Use of a Connected Pillbox On Medication Adherence
Diabetes Mellitus · Hypertension · Hyperlipidemia
Primary: Percent of Participants With Adherence at Month 6 — 91; 40 percent persistent on therapy — p=<0.05
N/A N=8 Tools to Improve Medication Continuity in Adolescents With ADHD
Attention Deficit Hyperactivity Disorder
Primary: Proportion of Days Covered With Medicine — 0.69 Proportion of days covered with medicine
Phase 2 N=51 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
Opioid Dependence
Primary: Number of Participants Retained in Study — 18 participants
N/A N=52 The Medication Metronome Project - Study to Facilitate Follow-up Testing Resulting From Prescribed Medications to Improve Patient Safety and Care
Diabetes Mellitus, Type 2 · Hypertension · Hyperlipidemia
Primary: Primary Effectiveness Outcome - LDL — 57.9; 54.8 percentage of time spent at goal
N/A N=66 Mobile Application to Enhance Medication Management
Medication Adherence · Mobile Application
Primary: Usability of the SAM App — 1.14; 1.32; 1.35; 1.81 score on a scale
N/A N=1,525 The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances
Economics · Fraud · Delivery of Health Care
Primary: 30-day Equivalent Prescribing of Schedule II Controlled Substances — 461.1; 450.0 30-day equivalent prescription fills
Phase 4 N=60 Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users
Abuse Potential
Primary: Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax). — 54.30; 90.85; 72.53; 76.05 Score on a 100 mm scale — p=<0.0001